BioCentury
ARTICLE | Emerging Company Profile

Mapping tumor markers

BioGraph 55 is creating tumor maps to identify biomarkers and novel targets

September 13, 2018 8:42 PM UTC

BioGraph 55 Inc. is mapping immune cells in the tumor microenvironment to identify cell-to-cell interaction patterns that can help match patients to existing therapies and identify novel therapeutic targets. The newco is developing a pipeline with an initial focus on cancer patients who express PD-1 or PD-L1 but don’t respond to PD-1 or PD-L1 inhibitors.

“The problem that we saw in the clinic was that we were targeting a single protein, without understanding how tumors are organized, which removes the context of when and where that protein is being used,” said BioGraph 55 CEO Paul Tumeh. “We’re now introducing a variable that’s been largely ignored historically in target discovery, and that is space or locality.”...